Novel antimicrobial target discovery by an integrated approach.

该项目旨在发现bdm - 1的分子靶点，bdm - 1是澳大利亚初创公司BioDiem Ltd.发现的一种新型抗菌候选药物。bdm - 1对许多耐药细菌和真菌微生物有活性，目前正处于临床前开发阶段。然而，缺乏抗性表型使得BDM-I的作用机制难以确定。该项目计划采用一种综合方法，将新型的硅筛选技术与实验验证相结合。预计项目成果将包括首个整合靶标和配体相似性的计算方法，用于蛋白质组级靶标和非靶标发现，这将推动全球对抗耐药微生物的斗争。

The project aims to uncover the molecular targets of BDM-I, a novel antimicrobial candidate discovered by the start-up Australian company BioDiem Ltd. BDM-I is active against many drug resistant bacterial and fungal microorganisms and it is currently in pre-clinical development. However, the lack of resistant phenotypes makes it difficult to identify BDM-I’s mechanism of action. The project plans to use an integrated approach that combines a novel technique of in silico screening with experimental validation. Project outcomes are anticipated to include the first computational method to integrate target and ligand similarity for proteome-scale target and off-target discovery, which will advance the global fight against drug-resistant microorganisms.